TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04401891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal pre-operative education
Description: One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
Study: NCT04429191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Description: Procedure: single intravenous infusion of JSP191 antibody
Study: NCT01751009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements
Description: Sprinkles with Vitamin A
Study: NCT01458327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: 125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy
Study: NCT00287768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + S-1
Description: Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 po days 1-28 every 6 weeks
Study: NCT01751009

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles without Vitamin A
Description: Active comparator
Study: NCT00352001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Study: NCT03066193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol and Palmitoylethanolamide
Description: Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks; in addition, participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
Study: NCT01243723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eductyl suppository
Description: One suppository every morning during 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Description: One suppository every morning during 21 days
Study: NCT02118974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy
Study: NCT03331900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR388
Description: Administered as oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as oral capsule
Study: NCT03415282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% topical ointment
Description: RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
Study: NCT05659823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl-morphine elective group
Description: Guideline recommended analgesia in elective caesarian section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl elective group
Description: Current analgesia in elective caesarian section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl emergency group
Description: Current analgesia in emergency caesarian section.
Study: NCT02318966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medical Food - Glycosade
Description: double blind randomised crossover of 2 starches - glycosade and UCCS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medical Food - Glycosade
Description: double blind randomised crossover of 2 starches - glycosade and UCCS
Study: NCT03094741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CancerLife
Description: CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
Study: NCT00718510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: 3 grams, twice daily, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Arginine
Description: 3 grams, twice daily, oral administration
Study: NCT03170700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program with in-person parental feeding content
Description: Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
Study: NCT00694980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Intravenous and subcutaneous escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuMAb Beta7
Description: Intravenous and subcutaneous escalating doses
Study: NCT00655564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose).
Study: NCT01166308

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Stereotactic Radiotherapy (FSRT)
Description: Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
Study: NCT03252236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Modified 12-form Yang style Tai Chi.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
Study: NCT04559802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmucosal Technique
Description: Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submerged Technique
Description: Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
Study: NCT02463604

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Coronary Angiography
Description: Coronary angiography is performed following usual site standards

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography
Description: Coronary angiography is performed following usual site standards
Study: NCT04252196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: usability evaluation of medical device
Description: participants interact with medical device and rate it for usability
Study: NCT00924820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein over about 1 hour, every 2 weeks.
Study: NCT06005077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Massage Group
Description: While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Massage Group
Description: While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Warm Compress Application Group
Description: Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal Massage and Perineal Warm Compress Application Group
Description: When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
Study: NCT00563602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic guided therapy
Description: To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic guided therapy
Description: To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)
Study: NCT03445663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 424
Description: Subjects will receive IV infusions of AMG 424
Study: NCT01906762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
Study: NCT02494882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT04347720

Intervention type: DRUG
Intervention: Acetaminophen
Description: Intravenous and oral formulations
Study: NCT02265393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTO-104
Study: NCT02494882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04437732

Intervention type: DEVICE
Group type: OTHER
Intervention: Apioc-P and Apioc-PT Contact Lens Design
Description: Novel soft contact lens design
Study: NCT03949634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Description: cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
Study: NCT04715321

Intervention type: OTHER
Intervention: CT perfusion examination
Description: CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
Study: NCT01693328

Intervention type: DRUG
Intervention: PecFent® (fentanyl) nasal spray
Study: NCT01782638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: deep brain stimulation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: deep brain stimulation
Study: NCT01987570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study: NCT03170700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program with online parental feeding content
Description: Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
Study: NCT01284517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Tablets 20-120 mg, PM dosing,daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent to Lurasidone dosing
Study: NCT03626792

Intervention type: OTHER
Group type: OTHER
Intervention: Hypertensive group
Description: Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
Study: NCT01886248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
Study: NCT00515879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions aim to help participants become more comfortable with social situations.
Study: NCT01987570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03179462

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork intake
Description: Each participant will consume 2 ounces of cooked lean pork.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed nuts intake
Description: Each participant will consume 1 ounce of mixed nuts.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tofu intake
Description: Each participant will consume 2 ounces of tofu.
Study: NCT04638218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training System
Description: The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
Study: NCT03039829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine nitrate, low dose
Description: Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate, high dose
Description: Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 6.0 grams (6.0 grams dextrose)
Study: NCT02300272

Intervention type: DEVICE
Intervention: Polysomnograph
Description: Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.

Intervention type: DEVICE
Intervention: Actiwatch
Description: This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
Study: NCT04491188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DE111
Description: 1 x10-9 CFU Bacillus subtilis DE111 probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT03687580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure Laser Pro
Description: The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
Study: NCT00644527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purpose designed music and sound listening program
Description: Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purpose designed music and sound listening program
Description: Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham music for depression
Description: Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
Study: NCT00978120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine high dose
Description: 30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
Study: NCT03626792

Intervention type: OTHER
Group type: OTHER
Intervention: Normotensive group
Description: Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
Study: NCT02285335

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GINST
Description: The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
Study: NCT00978120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine low dose
Description: 15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
Study: NCT04343508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified rice
Description: 100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
Study: NCT04232761

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Drug administration as determined by treating physician
Study: NCT00673712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Sternal Block
Description: Elastomeric Pump for Continuous Infusion of Local Anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based analgesia
Description: Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN
Study: NCT02435615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaniSal Oral Fluid Collector
Description: SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
Study: NCT01855737

Intervention type: DRUG
Intervention: Warfarin
Description: Prescribe warfarin to the patients who are needed.
Study: NCT01247649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Logic Continuous Glucose Monitoring System
Description: Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each